It is now accepted that bipolar disorder (BD) is associated with
|
|
- Shavonne Chapman
- 5 years ago
- Views:
Transcription
1 Trait-Related Decision-Making Impairment in the Three Phases of Bipolar Disorder Marc Adida, Fabrice Jollant, Luke Clark, Nathalie Besnier, Sébastien Guillaume, Arthur Kaladjian, Pascale Mazzola-Pomietto, Régine Jeanningros, Guy M. Goodwin, Jean-Michel Azorin, and Philippe Courtet Background: In bipolar disorder (BD), little is known about how deficits in neurocognitive functions such as decision-making are related to phase of illness. We predicted that manic, depressed, and euthymic bipolar patients (BPs) would display impaired decision-making, and we tested whether clinical characteristics could predict patients decision-making performance. Methods: Subjects (N 317; age range: years) including 167 BPs (45 manic and 32 depressed inpatients, and 90 euthymic outpatients) and 150 age-, IQ-, and gender-matched healthy control (HC) participants, were included within three university psychiatric hospitals using a cross-sectional design. The relationship between predictor variables and decision-making was assessed by one-step multivariate analysis. The main outcome measures were overall decision-making ability on the Iowa Gambling Task (IGT) and an index of sensitivity to punishment frequency. Results: Manic, depressed, and euthymic BPs selected significantly more cards from the risky decks than HCs (p.001, p.01, and p.05, respectively), with no significant differences between the three BD groups. However, like HCs, BPs preferred decks that yielded infrequent penalties over those yielding frequent penalties. In multivariate analysis, decision-making impairment was significantly (p.001) predicted by low level of education, high depressive scores, family history of BD, use of benzodiazepines, and nonuse of serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressants. Conclusions: BPs have a trait-related impairment in decision-making that does not vary across illness phase. However, some subtle differences between the BD groups in the individual deck analyses may point to subtle state influences on reinforcement mechanisms, in addition to a more fundamental trait impairment in risk-sensitive decision making. Key Words: Bipolar disorder, decision making, depression, euthymia, mania, neurocognition From the Mediterranean Institute of Cognitive Neurosciences (MA, NB, PM-P, RJ, J-MA), Department of Pharmacology and Neuropsychology of Emotions Related to Risk Taking and Reward, National Research Scientific Centre, and Department of Psychiatry (MA, NB, J-MA), Sainte-Marguerite Hospital, Mediterranean University, Marseille, France; Mental Health University Institute Douglas (FJ) and McGill Group for Suicide Studies, McGill University, Montréal, Canada; Department of Experimental Psychology (LC), University of Cambridge, Cambridge, United Kingdom; University Montpellier I (SG, PC), Emergency Department (SG, PC) of Academic Hospital Montpellier, and National Institute of Health and Medical Research U888 (SG, PC), Montpellier, France; University Department of Psychiatry (GMG), Warneford Hospital, Oxford, United Kingdom; and Centre Hospitalier Régional Universitaire Hôpital R. Debré (AK), Reims, France. Address correspondence to Marc Adida, M.D., Ph.D., Sainte-Marguerite Hospital, Department of Psychiatry, Mediterranean University, 270 Bd de Sainte-Marguerite, Marseille, France; marc.adida@aphm.fr. Received Apr 22, 2010; revised Jan 12, 2011; accepted Jan 13, /$36.00 doi: /j.biopsych It is now accepted that bipolar disorder (BD) is associated with substantial alterations in neuropsychologic function. Whereas early studies focused on attentional, mnemonic, and executive domains, recent studies have highlighted the link between simple tests of risky decision-making and the manic phase of the illness (1,2). Although trait-related cognitive impairments have been reported in BD patients (BPs) (3,4), the nature and extent of decisionmaking dysfunction across the phases of the illness remain unclear. Some studies have shown that patients have impaired decisionmaking in both the manic (1,2, 5 7) and depressed (8) states, whereas others have reported conflicting results in patients in remission (9 13). It is also likely that other illness variables, such as number of episodes, severity of acute symptoms, type of medication, and family history of BD have an impact on decision-making cognition. To our knowledge, Yechiam et al. (13) are the only group that has used the same task to assess decision-making in both the acute and remitted state of BD. However, their study was limited by small group sizes and lack of power. Decision-making occurs when the individual has to select between multiple options associated with uncertain consequences. Laboratory tasks have been devised to assess competency in realworld decision-making and dissect some of cognitive processes involved. This study used the Iowa Gambling Task (IGT), a clinically sensitive tool that emulates real-world financial decision-making. Each choice leads to monetary gains or losses. Differences in IGT performance are seen in individuals with neuropsychiatric disorders characterized by problems in impulse control and emotional regulation (14 17). Functional imaging (17,18) and brain lesion studies have implicated distributed neural circuitry in supporting successful decision-making on the IGT, including the ventromedial (ventromedial prefrontal cortex [VMPFC]) (19) and ventrolateral prefrontal cortex (20), and amygdala (21), areas that have been associated with BD (22). On the basis of these findings, we predict that decision-making is impaired in the acute phases but also in remission of BD. The IGT results were further analyzed in relation to sociodemographic and clinical variables in BD patients. Methods and Materials Participants The study population comprised 167 BPS (98 women and 69 men; age range: years) and 150 healthy volunteers (75 women and 75 men; age range: years; see power analysis in Section 1 of Supplement 1). Diagnostic assessment of the patients BIOL PSYCHIATRY 2011;70: Society of Biological Psychiatry
2 358 BIOL PSYCHIATRY 2011;70: M. Adida et al. was initially performed by an experienced psychiatrist and was confirmed using the Structural Clinical Interview for DSM-IV (23). Exclusion criteria included a history of head injury or neurologic disease. All subjects had normal thyroid function. No patient had received electroconvulsive therapy or had a history of substance abuse within the previous 6 months. Control subjects had no psychiatric history, no first-degree relatives with BD, and were not taking any drugs that might affect cognition. The study was approved by the local ethics committees. After complete description of the study to the subjects, written informed consent was obtained. Manic Group Forty-five inpatients suffering from mania were included (30 from Marseille University Department of Psychiatry and 15 from Oxford University Department of Psychiatry). All patients met the DSM-IV criteria for bipolar I disorder, manic episode, with a score greater than 12 on the Young Mania Rating Scale (YMRS) (24) and less than 7 on the Hamilton Depression Rating Scale (HDRS, 17 items) (25). The manic group comprised 22 women and 23 men (age range: years). Thirty-two of the 45 patients were receiving antipsychotic drugs at the time of testing. No patients were receiving D 2 -agonist antipsychotics. Fifteen patients were receiving typical antipsychotics. Seventeen patients were receiving the atypical antipsychotics risperidone (n 1), clozapine (n 1), and olanzapine (n 15). Fourteen of these patients were also receiving lithium, valproate, carbamazepine, or a combination of these drugs. Eleven patients were receiving lithium, valproate, carbamazepine, or a combination of these drugs without a neuroleptic. Twentythree patients were receiving a benzodiazepine, typically diazepam or lorazepam. Depressed Group Thirty-two inpatients suffering from bipolar depression were included (16 from Marseille University Department of Psychiatry and 16 from Montpellier University Department of Psychiatry). All patients met the DSM-IV criteria for bipolar I disorder, depressed episode, with a score of greater than 12 on the HDRS) (25) and less than 7 on the YMRS (24). The depressed group comprised 18 women and 14 men (age range: years). Sixteen of the 32 patients were receiving antipsychotic drugs at the time of testing. No patients were receiving typical antipsychotics. Sixteen patients were receiving the atypical antipsychotics aripiprazole (n 3), olanzapine (n 7), risperidone (n 4), amisulpride (n 1), and clozapine (n 1). Fourteen were also receiving lithium, valproate, carbamazepine, or a combination of these drugs. Thirteen patients were receiving lithium, valproate, carbamazepine, or a combination of these drugs without a neuroleptic. Sixteen patients were receiving lithium, valproate, carbamazepine, or a combination of these drugs with an antidepressant. Sixteen patients were receiving a benzodiazepine. Euthymic Group Ninety bipolar patients in clinical remission were included (60 from Montpellier University Department of Psychiatry and 30 from Oxford University Department of Psychiatry). All patients were euthymic at the time of testing, as defined by a score of less than 8 on the HDRS (25) and less than 8 on the YMRS (24), and met the DSM-IV criteria for bipolar I disorder, euthymic state. The euthymic group comprised 58 women and 32 men (age range: years). Fiftytwo of the 90 patients were receiving lithium, valproate, carbamazepine, or a combination of these drugs. Twenty-two patients were also receiving antipsychotics. Six patients were receiving typical antipsychotics. Seventeen patients were receiving the atypical antipsychotics aripiprazole (n 1), risperidone (n 5), and olanzapine (n 11). Thirty patients were receiving lithium, valproate, carbamazepine, or a combination of these drugs without an antipsychotic. Thirty-eight patients were receiving lithium, valproate, carbamazepine, or a combination of these drugs with an antidepressant. Twenty-three patients were receiving a benzodiazepine. Control Group One hundred fifty healthy volunteers were recruited as control subjects by advertisements in the three communities (15 from Marseille, 30 from Oxford, and 105 from Montpellier). Control subjects had no psychiatric or neurological history, no first-degree relatives with BD, and were not taking any drugs that might affect cognition. Procedure Patients mood was formally assessed using the YMRS and HDRS. Level of education and National Adult Reading Test (NART) (26) were used indirectly to assess premorbid intelligence level in the four groups (Table 1). NART Z scores were defined as the Z standardization scores of NART and fnart (French language adaptation of the NART) (27) scores, for English and French participants, respectively. Descriptive data for the 30 manic patients from Marseille, 15 manic and 30 euthymic patients from Oxford, and 60 euthymic patients from Montpellier have been published previously (1,5,12,14). Iowa Gambling Task The computerized version of the IGT (19) was used in which the participant plays for a pretend monetary reward. The participant is required to make a series of 100 choices from four decks of cards, labeled A, B, C, and D. Each card choice results in a monetary win, but occasional choices also result in monetary loss, and the four decks differ in the profile of wins and losses. At the start of the task, the participant has no information about the four decks and must learn to choose advantageously based on trial-by-trial feedback. Penalties begin after 15 picks of cards. Decks A and B are associated with high immediate wins ($100/ choice) but occasionally larger penalties that result in a net loss over time. Decks C and D are associated with smaller immediate wins ($50/choice) but lower long-term losses, such that participants accumulate gradual profit from choosing these decks. Decks B and D provide low-frequency but high-magnitude penalties (with a ratio of total wins to total losses higher in deck D than in deck B, whereas decks A and C provide high-frequency but lowmagnitude penalties (with a ratio of total wins to total losses higher in deck C than deck A). Thus, profitability of the decks (C D vs. A B) is orthogonalized from punishment frequency/magnitude (B D vs. A C). Statistical Analysis Choices in the IGT were analyzed for individual decks A, B, C, and D (Section 2 of Supplement 1), over five blocks of 20 trials (Figure 1) and over 100 picks of cards (Figure 2), and classified as advantageous ( safe ) for decks C and D and disadvantageous ( risky ) for decks A and B. The overall net score or decision-making ability is the difference between the total number of advantageous and disadvantageous choices. Net scores were calculated for each block of 20 trials (Figure 1), for the first 40 and the last 60 trials (Figure 3, Section 3 of Supplement 1). Data were also analyzed in terms of sensitivity to punishment frequency by calculating a difference score [(B D)
3 M. Adida et al. BIOL PSYCHIATRY 2011;70: Table 1. Demographic and Clinical Characteristics of Manic, Depressed, and Euthymic Bipolar Patients, and Healthy Control Subjects Manic (n 45) Depressed (n 32) Euthymic (n 90) Control (n 150) Analysis Characteristic Mean SD Mean SD Mean SD Mean SD F df p Age (years) , Level of Education (years) , NART (Z score) a , Number of Manic Episodes Number of Depressive Episodes Age at Onset of Bipolar Disorder (Years) YMRS Score HDRS Score N % N % N % N % 2 df p , Sex , Male Female Medication Antipsychotic (D1/D2/D3/D4/ D5 Ki values) b,c D2 Antagonist , Typical: Haloperidol (83/2/12/ , /147) Atypical , Risperidone (60/4.9/12.2/ , /16) Amisulpride ( 10 4 /1.3/2.4/ , ) Clozapine (189/431/646/39/ , ) Olanzapine (58/72/63/17.1/ , ) D 2 Agonist Aripiprazole (387/0.95/4.9/ , / 10 3 ) Lithium , Anticonvulsant , Antidepressant , SSRI , SNRI , Tricyclic , Other AD , Benzodiazepine , Anticholinergic , AD, antidepressant; D 2, dopamine receptor subtype 2; HDRS, Hamilton Depression Rating Scale; K i, inhibitor dissociation constant; NART, National Adult Reading Test; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin and norepinephrine reuptake inhibitor; Euthymic; YMRS, Young Mania Rating Scale. a NART score assesses premorbid IQ. NART Z scores were defined as the Z standardization scores of NART and fnart (French language adaptation of the NART) scores, for English and French participants, respectively. b The D j -inhibitor constant K i of an antipsychotic is the concentration of that antipsychotic needed to inhibit D j receptor (j 1 5). K i values are reported in nanomolar units. Classically, the potency of an antipsychotic is indicated by the D 2 K i. The higher is the K i, the lower is the potency. An antipsychotic is said to be D 2 specific when D 2 K i is higher than D 1,D 3,D 4, and D 5 K i. For example, we may infer from the values between brackets, that amisulpride is D 2 - and D 3 -specific. c K i values determined by the National Institute of Mental Health (NIMH) Psychoactive Drug Screening Program. K i values selected were those listed as NIMH Psychoactive Drug Screening Program (PDSP) assay certified data, determined from assays using the cloned human receptors with drug of interest as test ligands. For K i values for which PDSP certified assay data were not listed, the average K i value from assay data compiled on the PDSP website using the cloned human receptors with drug of interest as the test ligand was used.
4 360 BIOL PSYCHIATRY 2011;70: M. Adida et al. Figure 1. Number of cards selected in individual deck A, B, C, and D and decision-making ability on the Iowa Gambling Task (IGT), in the manic, depressed, and euthymic bipolar patients (BPs), and healthy controls (HCs), graphed as a function of trial block. a,b (A) In HCs, the number of cards selected changed significantly over the course of the task in deck A (one-way analysis of variance [ANOVA] for repeated measures F 18.17, df 4, p.001), deck B (one-way ANOVA for repeated measures F 7.40, df 4, p.001), deck C (one-way ANOVA for repeated measures F 10.95, df 4, p.001), and D (one-way ANOVA for repeated measures F 4.77, df 4, p.01). (B) In euthymic BPs, the number of cards selected changed significantly over the course of the task in deck A (one-way ANOVA for repeated measures F 3.42, df 4, p.05), deck B (one-way ANOVA for repeated measures F 7.57, df 4, p.001), deck C (one-way ANOVA for repeated measures F 6.94, df 4, p.001), and deck D (one-way ANOVA for repeated measures F 13.69, df 4, p.001). (C) In manic BPs, the number of cards selected changed significantly over the course of the task in deck C (one-way ANOVA for repeated measures F 2.46, df 4, p.05) but not in deck A (one-way ANOVA for repeated measures F 1.70, df 4, p.15), deck B (one-way ANOVA for repeated measures F 1.19, df 4, p.32), and deck D (one-way ANOVA for repeated measures F 1.31, df 4, p.27). (D) In depressed BPs, the number of cards selected changed significantly over the course of the task in deck D (one-way ANOVA for repeated measures F 4.00, df 4, p.01) but not in deck A (one-way ANOVA for repeated measures F 2.08, df 4, p.16), deck B (one-way ANOVA for repeated measures F 2.50, df 4, p.06), and deck C (one-way ANOVA for repeated measures F.27, df 4, p.6). (E) Net scores changed significantly over the course of the task in the HCs (one-way ANOVA for repeated measures F 38.3, df 4, p.001) but not in the manic (one-way ANOVA for repeated measures F 4.8, df 4, p.24), depressed (one-way ANOVA for repeated measures F 3.1, df 4, p.13), and euthymic BPs (one-way ANOVA for repeated measures F 1.4, df 4, p.06). a Choices in the IGT were analyzed for each individual deck A, B, C, and D over 100 picks of cards and for each block of 20 trials and classified as disadvantageous for decks A and B (the risky decks are associated with high immediate wins but occasionally larger penalties that result in a net loss over time) and as advantageous for decks C and D (the safe decks are associated with smaller immediate wins but negligible long-term losses that results in gradual profit). B and D are decks with low-frequency/high-magnitude penalties, and A and C are decks with high-frequency/low-magnitude penalties. Penalties begin after 10 picks of cards. b *p.05, **p.01, and ***p.001. (A C)], where a positive score indicates a preference for lowfrequency/high-magnitude penalties and a negative score a preference for high-frequency/low-magnitude penalties. The difference score [(B D) (A C)] were calculated for the first 40 and the last 60 trials (Figure 4, Section 3 of Supplement 1). The demographic, clinical, and cognitive variables were normally distributed (as assessed by the Kolmogorov Smirnov test and visual inspection) and were analyzed with parametric statistical tests with a threshold of p.05 (two-tailed). Age, level of education, and NART Z score for the manic, depressed, and euthymic patients and for control subjects were compared by one-way ANOVA, while gender and medication received were compared using chi-squared tests. Individual deck (Section 2 of Supplement 1) and IGT summary measures were analyzed using analysis of variance (ANOVA) with group (manic, depressed, euthymic, control) as a between-subjects factor and block (1 20, 21 40, 41 60, 61 80, and ) as a within-subjects factor. Sensitivity to punishment frequency scores were also compared with the value zero using single sample t tests. Post hoc Tukey tests of honestly significant differences (HSD) were performed to determine significant group differences and to control for Type I error (28). Univariate analysis with Pearson s correlations was performed to test for associations between IGT net score for the 165 bipolar patients and demographic and clinical variables (gender, age, level of education, NART Z score, number of manic episodes, number of depressive episodes, total number of admissions, age at onset, family history of BD, HDRS score, YMRS score, alcohol misuse history, drug misuse history, suicide attempt history, use of selective serotonin reuptake inhibitor (SSRI) antidepressant, use of serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressant, use of tricyclic antidepressant, use of other antidepressant, use of aripiprazole, use of haloperidol, use of olanzapine, use of clozapine, use of amisulpride, use of risperidone, use of anticonvulsant, use of lithium, use of anticholinergic, and use of benzodiazepine). A threshold of p.2 (29) was set to select variables for multivariate regression analysis. One-step multivariate linear regression analysis was then carried out to determine how much of the variation in IGT net score for bipolar patients could be explained and which demographic and clinical variables might predict variations in decisionmaking ability in BPs. Results Demographic and Clinical Characteristics The demographic and clinical characteristics of the manic, depressed, euthymic, and control groups are shown in Table 1. There was no significant between-group difference with respect to age, level of education, NART Z score, and sex ratio. For manic patients, mean YMRS score was and mean HDRS score was Nine patients were experiencing a first episode of mania, and 22 had a manic episode with psychotic features. The manic group had experienced an average of manic episodes (range: 1 12) and depressive episodes (range: 0 9), with a mean age at onset of years (range: 15 38). For depressed patients, mean YMRS score was and mean HDRS score was The depressed group had experienced an average of manic episodes (range: 1 10) and depressive episodes (range: 0 13), with a mean age at onset of years (range: 15 45). For euthymic patients, mean YMRS score was and mean HDRS score was The euthymic group had experienced an average of manic episodes (range: 0 9) and depressive episodes (range: 1 9), with a mean age at onset of years (range: 16 45).
5 M. Adida et al. BIOL PSYCHIATRY 2011;70: Figure 2. Number of cards selected in individual decks A, B, C and D, and decision-making ability on the Iowa Gambling Task (IGT) in the manic, depressed, and euthymic bipolar patients (BPs) and healthy control subjects (HCs), over 100 picks of cards. a,b,c,d (A) One-way analysis of variance (ANOVA) revealed significant differences in deck A overall score between the four groups [F(3,313) 3.24, p.05], and post hoc Tukey tests of honestly significant differences (HSD) revealed that manic BPs selected significantly more cards from the deck A than did HCs (p.05; effect size [d].48), with no significant differences between depressed BPs and HCs (p.99), euthymic BPs and HCs (p.43), or depressed and euthymic BPs (p.73). (B) One-way ANOVA revealed significant differences in deck B overall score between the four groups [F(3,313) 7.50, p.001] and post hoc Tukey tests of HSD revealed that manic (p.01; d.68), depressed (p.01; D.79), and euthymic (p.05; d.44) BPs selected significantly more cards from the deck B than HCs with no significant differences between manic and depressed (p.94), manic and euthymic (p.58), or depressed and euthymic (p.28) BPs. (C) One-way ANOVA revealed no significant differences in deck C overall score between the four groups [F(3,313) 2.45, p.071]. (D) One-way ANOVA revealed significant differences in deck D overall score between the four groups [F(3,313) 4.42, p.01], and post hoc Tukey tests of HSD revealed that manic BPs selected significantly fewer cards from the deck D than HCs (p.01; effect size d.53) with no significant differences between depressed BPs and HCs (p.40), euthymic BPs and HCs (p.08), or depressed and euthymic (p.99) BPs. One-way ANOVA revealed highly significant differences in decision-making ability between the four groups [F(3,313) 8.1, p.001]. Post hoc Tukey tests of HSD revealed that manic (p.001; effect size d.68), depressed (p.01; d.59), and euthymic (p.05; D.35) BPs selected significantly more cards from the risky decks than HCs with no significant differences between manic and depressed (p.97), manic and euthymic (p.23), or depressed and euthymic (p.62) BPs. a (E) Choices in the IGT were analyzed for each individual deck (A, B, C, and D) over 100 picks of cards and for each block of 20 trials and classified as disadvantageous for decks A and B (the risky decks are associated with high immediate wins but occasionally larger penalties that result in a net loss over time) and as advantageous for decks C and D (the safe decks are associated with smaller immediate wins but negligible long-term losses that results in gradual profit). B and D are decks with low-frequency/high-magnitude penalties, whereas decks A and C are decks with high-frequency/low-magnitude penalties. Penalties begin after 10 picks of cards. b *p.05, **p.01, and ***p.001. c Cohen s d effect size is calculated as the difference between each of the three patient groups and the control group. The value of d is typed at the top of each patient group s histogram. d Budescu (59) reported that for normally distributed populations with heterogeneous variances, substituting for, in the denominator of equation f m /, the square root of the n i -weighted population variance, results in good power approximations. IGT Performance Decision-Making Ability. Net score changed significantly over the course of the task in the healthy control group (one-way ANOVA for repeated measures F 38.3, df 4, p 10 3 ) but not in the manic (F 4.8, df 4, p.24), depressed (F 3.1, df 4, p.13), and euthymic groups (F 1.4, df 4, p.06; Figure 1E) (Figure 1A, 1B, 1C, and 1D, see comments in Section 2 of Supplement 1). When IGT performance was analyzed according to the decisionmaking ability, one-way ANOVA revealed highly significant differences in decision-making ability between the four groups ([F(3,313) 8.1, p.001], and post hoc Tukey tests of HSD revealed that manic (p.001; effect size [d].68), depressed (p.01; d.59), and euthymic (p.05; d.35) BPs selected significantly more cards from the risky decks than healthy control subjects, with no significant differences between manic and depressed (p.97), manic and euthymic (p.23), or depressed and euthymic (p.62) BPs (Figure 2E) (Figure 2A, 2B, 2C and 2D, see comments in Section 2 of Supplement 1). IGT performance was also analyzed according to the decisionmaking ability, over the first 40 picks and over the last 60 picks of cards (Figure 3, see comments in Section 3 of Supplement 1). Sensitivity to Punishment Frequency When IGT performance was analyzed according to sensitivity to punishment frequency, all four groups preferred decks offering low-frequency penalties (B D) over those with high-frequency penalties (A C; t 5.0, p.001; t 6.0, p.001; t 7.5, p.001; and t 7.4, p.001 for manic, depressed, and euthymic BPs and healthy volunteers, respectively), with no significant differences between the four groups [one-way ANOVA F(3,313) 1.5, p.22] (Figure 4A) (Figure 4B and 4C, see comments in Section 3 of Supplement 1). Association Between IGT Performance and Clinical Variables Univariate analysis of sociodemographic and clinical variables was carried out against IGT net score for the 167 BD patients. Gender (females performed worse; r.23, p.01), level of education (r.26, p.001), NART Z score (r.17, p.05), total number of admissions (r.22, p.05), HDRS score (r.25, p.01), YMRS score (r.28, p.01), use of benzodiazepine (r.29, p.001), and family history of BD (r.22, p.05) correlated with IGT net score at p.05 and were subjected to multivariate analysis with age at onset and use of serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs; p.2). In multivariate analysis, level of education (.26, t 2.79, p.01), HDRS score (.24, t 2.46, p.05), family history of BD (.23, t -2.53, p.05), use of benzodiazepine (.19, t 1.93, p.05), and use of SNRI antidepressant (.21, t 2.29, p.05) were significant predictors of IGT net score in bipolar patients (Table 2). Discussion Impaired decision-making was detected in all three phases of BD. Risk-taking behavior is a diagnostic feature of mania, and depressed patients also exhibit difficulties in decision-making in their daily lives. The translation of these ecological observations to the laboratory is difficult. It is therefore relevant to report that, using an experimental paradigm to detect risky-choice preference, both manic and depressed patients showed lower scores than healthy volunteers. These findings in the acute phases of BD are broadly consistent with previous studies of decision-making deficits assessed with the IGT (1,5 7), with the Cambridge Gamble Task (6 8), and in relation to an increased sensitivity to error during a twochoice prediction task (2). In addition, we report impaired decisionmaking in euthymic patients, which is also in accordance with some
6 362 BIOL PSYCHIATRY 2011;70: M. Adida et al. Figure 3. Iowa Gambling Task (IGT) net score, in the manic, depressed, and euthymic bipolar patients (BPs) and healthy control subjects (HCs), over the first 40 and the last 60 picks of cards, a,b,c (A) One-way analysis of variance (ANOVA) revealed no significant differences in IGT net score between the four groups [F(3,313) 1.61, p.18] over the first 40 picks of cards. (B) One-way ANOVA revealed highly significant differences in IGT net score between the four groups [F(3,313) 7.9, p.001] over the last 60 picks of cards. Post hoc Tukey tests of honest significant difference revealed that manic (p.001), depressed (p.05), and euthymic (p.01) BPs selected significantly more cards from the risky decks than HCs with no significant differences between manic and depressed (p.86), manic and euthymic (p.57), or depressed and euthymic (p.99) BPs. a Choices in the IGT were analyzed for each individual deck (A, B, C, and D) over 100 picks of cards and for each block of 20 trials and classified as disadvantageous for decks A and B (the risky decks are associated with high immediate wins but occasionally larger penalties that result in a net loss over time) and as advantageous for decks C and D (the safe decks are associated with smaller immediate wins but negligible long-term losses that results in gradual profit). B and D are decks with low-frequency/high-magnitude penalties, whereas decks A and C are decks with high-frequency/low-magnitude penalties. Penalties begin after 10 picks of cards. b *p.05, **p.01, and ***p.001. c Budescu (59) reported that for normally distributed populations with heterogeneous variances, substituting for, in the denominator of equation f m /, the square root of the n i -weighted population variance, results in good power approximations. previous studies of decision-making deficits assessed with the IGT. Yechiam et al. (13) reported a similar decision-making impairment in 14 euthymic patients assessed with the IGT. Christodoulou et al. (10) reported an IGT score close to 0 in a group of 25 euthymic subjects. These findings suggest that decision-making alterations could be considered as a trait abnormality in BD. The failure of the BD patients to select from the safe decks may reflect a classic myopia for the future (30), that is, the inability to use outcome information to guide an advantageous long-term strategy, acting as a trait marker in BD. However, some subtle differences were observed between the BD groups in the individual deck analyses. First, all groups preferred the two decks that yielded infrequent penalties over those that yielded more frequent penalties. This indicates that bipolar patients appear to be normally sensitive to the impact of losses. Nevertheless, the depressed BD group exhibited a specific punishment-sensitive pattern of choice by selecting more cards in decks with low-frequency penalties (B, D) and fewer cards in decks with high-frequency penalties (A, C) than did other groups; this difference was statistically significant over the last 60 trials of the task. In contrast, manic bipolar patients were less likely to avoid low-magnitude/high-frequency punishments (A, C) and more likely to avoid high-magnitude/low-frequency (B, D), as if they were less sensitive than other bipolar groups to the impact of frequent and small losses. These differences may point to subtle state influences on reinforcement mechanisms that operate during decision-making, over and above a more fundamental trait impairment in risk-sensitive decision-making. This is also the first report of any associations between decisionmaking impairment in BD and clinical variables. Five independent variables were found to be associated with IGT overall score in the regression analysis: high depression ratings, low level of education, use of benzodiazepines, nonuse of SNRIs, and family history of BD. Several additional factors that were associated with IGT performance in the univariate, but not the multivariate, analysis, were probably intercorrelated with one or more of those predictors. Interestingly, a relationship was previously reported in BD between the number of episodes and the severity of depression, which could be explained by the presence of residual symptoms from prior depressive episodes (31). Moreover, women with BD may experience more depressive episodes than men (32). Thus, in our study, high levels of depression (HDRS score) might be correlated with both total number of admissions and gender. In support of this, our group of depressed patients exhibited a greater number of previous depressive episodes and a higher proportion of females in comparison with the manic group. Similarly, the association with level of education is consistent with previous reports of a positive correlation between performance in cognitive and executive function tests and level of education in BD (33). However, its association with decision-making is disputed (34). The association between the use of benzodiazepine and impaired decision-making is consistent with previous reports of these drugs to have an adverse effect on psychomotor ability and memory (35). The positive correlation between the use of SNRI antidepressants and decision-making ability in BD is consistent with the psychopharmacology of SNRI antidepressant action. Although SNRI antidepressants are commonly called dual-action serotonin-norepinephrine agents, they actually have a third action on dopamine in the prefrontal cortex, but not elsewhere in the brain: they enhance dopamine levels and increase dopamine s diffusion radius, probably enhancing the ability of dopamine to regulate cognition (36). Furthermore, a large increase of dopamine release may facilitate learning in corticostriatal systems (37) when salient stimuli occurred. This salience may be produced by unexpected or highmagnitude rewarding or punishing events or by novelty (38,39). Thus, boosting dopamine with SNRIs may improve IGT performance; however, we assume that excessive tonic dopamine might lead to reduced punishment sensitivity.
7 M. Adida et al. BIOL PSYCHIATRY 2011;70: Figure 4. Difference score [(B D) (A C)] on the Iowa Gambling Task (IGT) in the manic, depressed, and euthymic bipolar patients (BPs) and healthy controls (HCs) over 100 picks of cards (sensitivity to punishment frequency), over the first 40, and over the last 60 picks of cards. a,b (A) All four groups preferred decks offering low-frequency/high-magnitude penalties (decks B and D) over those with high-frequency/low-magnitude penalties (decks A and C; t 5.0, p.001; t 6.0, p.001; t 7.5, p.001; and t 7.4, p.001 for manic, depressed, and euthymic BPs and HCs, respectively), with no significant differences between the four groups [one-way analysis of variance (ANOVA) F(3,313) 1.5, p.22]. (B) One-way ANOVA revealed no significant differences in [(B D) - (A C)] score between the four groups [F(3,313).53, p.66] over the first 40 picks of cards. (C) One-way ANOVA revealed a significant difference in [(B D) (A C)] score between the four groups [F(3,313) 2.75, p.05] over the last 60 picks of cards. Post hoc Tukey tests of honest significant difference revealed a significant difference between depressed (p.05) but not manic (p.98) or euthymic (p.99) BPs and HCs, with a significant difference between depressed and euthymic (p.05) but not between manic and depressed (p.19) or between manic and euthymic (p.98) BPs. a Choices in the IGT were analyzed for each individual deck (A, B, C, and D) over 100 picks of cards and for each block of 20 trials and classified as disadvantageous for decks A and B (the risky decks are associated with high immediate wins but occasionally larger penalties that result in a net loss over time) and as advantageous for decks C and D (the safe decks are associated with smaller immediate wins but negligible long-term losses that results in gradual profit). B and D are decks with low-frequency/high-magnitude penalties, whereas decks A and C are decks with high-frequency/low-magnitude penalties. Penalties begin after 10 picks of cards. b * p.05. The association between family history of BD and impaired decision-making observed here also parallels the genetics of mood disorders in which bipolar patients with a family history of BD exhibit enrichment of genetic effects compared with bipolar patients without a family history of BD (40). One target for future research will be to determine whether impaired decision-making impairment might be a candidate endophenotype to BD. This is suggested by Lovallo et al. (41) in alcoholic patients. According to Hasler et al. (42), a dysmodulation of motivation and reward might be a candidate endophenotype to BD. Thus, we would recommend that future studies test for other criteria for the identification of Table 2. Multivariate Linear Regression Analysis of Demographic and Clinical Variables Associated with Decision-Making Ability in Patients with Bipolar Disorder a Analysis Variable t p Constant Sex Level of Education (years) b NART (Z score) c YMRS Score HDRS Score b Total No. Hospital Admissions Age at Onset of BD (years) Familial History of BD b Medication Received SNRI AD b Benzodiazepine b AD, antidepressant; BD, bipolar disorder; HDRS, Hamilton Depression Rating Scale; NART, National Adult Reading Test; SNRI, serotonin and norepinephrine reuptake inhibitor; YMRS, Young Mania Rating Scale. a The significance of the explained amount of variance (R 2 ) was assessed by analysis of variance [F(7,92) 6.37; p.001]. b R 2.41; adjusted R c NART score assesses premorbid IQ. NART Z scores were defined as the Z standardization scores of NART and fnart (French language version) scores, for English and French participants, respectively. endophenotype: heritability, cosegregation with BD within families, and presence in unaffected relatives at a higher rate than in the general population (43). Previous studies on decision-making in patients with psychiatric disorders suggest that age (44), female sex (45), drug misuse (46), and suicide attempt (14) are associated with disadvantageous decision-making. In this study, these variables were not related to IGT performance. Age may be a critical factor in adolescent (47) and in old-age individuals (48) who are not represented in our study. Female sex was associated with a lower IGT net score in bipolar patients and control subjects, but the effect did not survive multivariate analysis. The lack of replication in drug misuse and suicide attempt may be related to a strong effect of BD leading to a ground effect in these patients. Brain lesion studies implicate distributed neural circuitry in supporting successful decision-making on the IGT, including the VMPFC (20,49) and amygdala (21). Several functional imaging studies of manic (22), depressed (22), and euthymic (22) patients have also implicated VMPFC dysfunction. Thus, VMPFC attenuation may represent a trait feature of the disorder (22). In support of this hypothesis, Stanfield et al. (50) reported gray matter deficits in the bilateral VMPFC in 66 bipolar patients in different phases of the disorder. Our findings are consistent with a model of VMPFC abnormalities in mania, bipolar depression, and euthymia, leading to impaired decision-making. This study has several limitations. First, all bipolar patients were receiving some type of medication. Although univariate analysis was unable to detect any differences between patients who were receiving (71% of manic, 50% of depressed and 24% of euthymic BPs) or not receiving antipsychotic medication, there is a strong case for reinforcement learning performance and decision-making ability to be sensitive to dopaminergic agents (51 53). Thus, comparison of decision-making ability between BD subgroups might be confounded by this point. In addition, we detected differences between BD patients who were receiving or not receiving benzodiazepines. These drugs have been reported to have an adverse effect on psychomotor ability and memory (35) and for anticonvulsants on general cognitive functioning (54), although the importance of
8 364 BIOL PSYCHIATRY 2011;70: M. Adida et al. these effects is disputed (35). Second, we did not use any complementary neuropsychological test with the IGT to characterize BD patients in this study. Fellows et al. (55) showed that deficit in reversal learning was an important mechanism underlying the difficulties in the IGT. Maia et al. (53) reported that IGT might assess not only pure implicit decision-making, on the basis of somatic markers inaccessible to consciousness, but both conscious and nonconscious knowledge. Thus, impaired decision-making in BPs may be associated with defects in reversal learning or explicit memory. From this study, we cannot determine whether deficits reported in BPs are specific abnormalities in decision-making (and what subprocesses may be implicated) or refer to a more global impairment in cognitive control processes. Thus, further research should include additional investigations. Third, the multicenter nature of the study might have introduced potential site differences in clinical characteristics and IGT performance of bipolar and control participants. The only difference detected here between IGT net scores was for the 30 British euthymic subjects compared with the 60 French euthymic patients but was explained by level of education. Fourth, the study did not assess smoking status, which should be considered in further studies. Fifth, there is a strong case for an ecologically valid support for a link between cognitive and psychosocial functioning in BD (56,57). Further research should test for an association between decision-making ability and psychosocial functioning in BD (58). In conclusion, manic, depressed, and euthymic BD patients showed poor performance in a laboratory test (IGT) of decisionmaking. Impaired decision-making was correlated with high depression scores, low level of education, use of benzodiazepines, nonuse of SNRIs, and family history of BD. Thus, the decision-making capacity of patients with BD is modulated by state, education/ IQ, and medication. The observation that trait-related deficits in BD are characterized by an objective failure to weigh costs versus benefit in a simple game is of clinical interest and may represent a future therapeutic target. This work was supported by National Research Scientific Centre (CNRS), Marseille, France; National Institute of Health and Medical Research, Montpellier, France; Academic Hospital (CHU) Lapeyronie, CHU Sainte-Marguerite, and Oxford University. We thank Professors C. Lançon and J. Naudin for their collaboration; Dr. Adéla Ionita and Mrs. Nadia Corréard, Nathalie Viglianese-Salmon, and Sara-Nora Elissalde for their help in assessment; Anderson Loundou from the Public Health Department, University of Marseille, for his help concerning statistics; and Professors A. Bechara and A. Damasio for the use of the Iowa Gambling Task. Philippe Courtet has accepted reimbursement for advice or participation in industry-supported symposia from most pharmaceutical companies with an interest in bipolar disorder or suicide in the past 5 years. Jean-Michel Azorin has accepted reimbursement for advice or participation in industry-supported symposia from most pharmaceutical companies with an interest in bipolar disorder in the past 5 years and holds grants from Lilly and Sanofi-Aventis. Luke Clark is a consultant for Cambridge Cognition. Guy M. Goodwin has accepted reimbursement for advice or participation in industry-supported symposia from most pharmaceutical companies with an interest in bipolar disorder in the past 5 years and holds grants from Sanofi-Aventis for the balance trial and from Servier. Marc Adida received grants from Lilly (Bourse Lilly en Santé Mentale 2008) and Servier (Bourses de l Institut Servier 2008 et 2009) for his postdoctoral years in United Kingdom. Fabrice Jollant, Nathalie Besnier, Sébastien Guillaume, Arthur Kaladjian, Pascale Mazzola-Pomietto, and Régine Jeanningros report no biomedical financial interests or potential conflicts of interest. Supplementary material cited in this article is available online. 1. Adida M, Clark L, Pomietto P, Kaladjian A, Besnier N, Azorin JM, et al. (2008): Lack of insight may predict impaired decision making in manic patients. Bipolar Disord 10: Minassian A, Paulus MP, Perry W (2004): Increased sensitivity to error during decision-making in bipolar disorder patients with acute mania. J Affect Disord 82: Wingo AP, Harvey PD, Baldessarini RJ (2009): Neurocognitive impairment in bipolar disorder patients: Functional implications. Bipolar Disord 11: Torres IJ, Boudreau VG, Yatham LN (2007): Neuropsychological functioning in euthymic bipolar disorder: A meta-analysis. Acta Psychiatr Scand Suppl: Clark L, Iversen SD, Goodwin GM (2001): A neuropsychological investigation of prefrontal cortex involvement in acute mania. Am J Psychiatry 158: Murphy FC, Rubinsztein JS, Michael A, Rogers RD, Robbins TW, Paykel ES, Sahakian BJ (2001): Decision-making cognition in mania and depression. Psychol Med 31: Rubinsztein JS, Fletcher PC, Rogers RD, Ho LW, Aigbirhio FI, Paykel ES, et al. (2001): Decision-making in mania: A PET study. Brain 124: Rubinsztein JS, Michael A, Underwood BR, Tempest M, Sahakian BJ (2006): Impaired cognition and decision-making in bipolar depression but no affective bias evident. Psychol Med 36: Jollant F, Guillaume S, Jaussent I, Bellivier F, Leboyer M, Castelnau D, et al. (2007): Psychiatric diagnoses and personality traits associated with disadvantageous decision-making. Eur Psychiatry 22: Christodoulou T, Lewis M, Ploubidis GB, Frangou S (2006): The relationship of impulsivity to response inhibition and decision-making in remitted patients with bipolar disorder. Eur Psychiatry 21: Rubinsztein JS, Michael A, Paykel ES, Sahakian BJ (2000): Cognitive impairment in remission in bipolar affective disorder. Psychol Med 30: Clark L, Iversen SD, Goodwin GM (2002): Sustained attention deficit in bipolar disorder. Br J Psychiatry 180: Yechiam E, Hayden EP, Bodkins M, O Donnell BF, Hetrick WP (2008): Decision making in bipolar disorder: A cognitive modeling approach. Psychiatry Res 161: Jollant F, Bellivier F, Leboyer M, Astruc B, Torres S, Verdier R, et al. (2005): Impaired decision making in suicide attempters. Am J Psychiatry 162: Bar-On R, Tranel D, Denburg NL, Bechara A (2003): Exploring the neurological substrate of emotional and social intelligence. Brain. 126: ( ). 16. Bolla KI, Eldreth DA, Matochik JA, Cadet JL (2005): Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 26: Ernst M, Bolla K, Mouratidis M, Contoreggi C, Matochik JA, Kurian V, et al. (2002): Decision-making in a risk-taking task: A PET study. Neuropsychopharmacology 26: Fukui H, Murai T, Fukuyama H, Hayashi T, Hanakawa T (2005): Functional activity related to risk anticipation during performance of the Iowa Gambling Task. Neuroimage 24: Bechara A, Damasio H, Tranel D, Damasio AR (1997): Deciding advantageously before knowing the advantageous strategy. Science 275: Lawrence NS, Jollant F, O Daly O, Zelaya F, Phillips ML (2009): Distinct roles of prefrontal cortical subregions in the Iowa Gambling Task. Cereb Cortex 19: Bechara A, Damasio H, Damasio AR, Lee GP (1999): Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. J Neurosci 19: Blumberg HP, Leung HC, Skudlarski P, Lacadie CM, Fredericks CA, Harris BC, et al. (2003): A functional magnetic resonance imaging study of bipolar disorder: State- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry 60: Spitzer RL, Williams JBW, Gibbon M, First MB (1996): SCID I, version 2.0 for DSM-IV. Indianapolis, IN: Lilly Research Laboratories. 24. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978): A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 133: Hamilton M (1960): A rating scale for depression. J Neurol Neurosurg, Psychiatry 23:56 62.
Decision making in euthymic bipolar I and bipolar II disorders
Psychological Medicine (2011), 41, 1319 1327. f Cambridge University Press 2010 doi:10.1017/s0033291710001832 ORIGINAL ARTICLE Decision making in euthymic bipolar I and bipolar II disorders D. J. Martino
More informationLithium in bipolar disorders.
Lithium in bipolar disorders. S. Mehdi Samimi Ardestani M.D. Department of Psychiatry, Shahid Beheshti University of Medical Science, Behavioral science research center Iranian psychiatric association,
More informationPerceived time pressure and the Iowa Gambling Task
Judgment and Decision Making, Vol. 3, No. 8, December 2008, pp. 636 640 Perceived time pressure and the Iowa Gambling Task Michael A. DeDonno and Heath A. Demaree Department of Psychology Case Western
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationDecision-making deficit in chronic migraine patients with medication overuse
DOI 10.1007/s10072-012-1071-4 ORAL COMMUNICATIONS Decision-making deficit in chronic migraine patients with medication overuse B. Biagianti L. Grazzi O. Gambini S. Usai R. Muffatti S. Scarone G. Bussone
More informationAffective Disorders.
Affective Disorders http://www.bristol.ac.uk/medicalschool/hippocrates/psychethics/ Affective Disorders Depression Mania / Hypomania Bipolar mood disorder Recurrent depression Persistent mood disorders
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Šagud M., Pivac N., Mustapić M., Nedić G., Mihaljević Peleš A., Kramarić M., Jakovljević M., Muck-Šeler D. (2008) The effect of lamotrigine on platelet serotonin concentration
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationThe Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients with Bipolar Disorder
Zahedan Journal of Research in Medical Sciences Journal homepage: www.zjrms.ir The Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients
More informationAging with Bipolar Disorder. Neha Jain, MD, FAPA Assistant Professor of Psychiatry, UConn Health
Aging with Bipolar Disorder Neha Jain, MD, FAPA Assistant Professor of Psychiatry, UConn Health Objectives Define bipolar disorder in the elderly Review comorbidities How does it differ from bipolar in
More informationPutative Mechanisms Underlying Risky Decision-Making in High Risk Drivers
Putative Mechanisms Underlying Risky Decision-Making in High Risk Drivers Samantha Ashley Wells 1,2, Thomas Gordon Brown 1,2 Psychiatry Department, McGill University Psychiatry Department, Douglas Hospital
More informationSupplementary Online Content
Supplementary Online Content Hulshoff Pol HE, van Baal GCM, Schnack HG, Brans RGH, van der Schot AC, Brouwer RM, van Haren NEM, Lepage C, Collins DL, Evans AC, Boomsma DI, Nolen W, Kahn RS. Overlapping
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationThe Somatic Marker Hypothesis: Human Emotions in Decision-Making
The Somatic Marker Hypothesis: Human Emotions in Decision-Making Presented by Lin Xiao Brain and Creativity Institute University of Southern California Most of us are taught from early on that : -logical,
More informationNeuRA Decision making April 2016
Introduction requires an individual to use their knowledge and experience of a context in order to choose a course of action 1. A person s ability to autonomously make decisions is referred to as their
More informationThe Role of Orbitofrontal Cortex in Decision Making
The Role of Orbitofrontal Cortex in Decision Making A Component Process Account LESLEY K. FELLOWS Montreal Neurological Institute, McGill University, Montréal, Québec, Canada ABSTRACT: Clinical accounts
More informationMood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationPractice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder,
Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Journal of the Academy of Child and Adolescent Psychiatry, 1997 Primary Authors: Jon McClellan MD
More informationTHE HAMILTON Depression Rating Scale
Reliability and Validity of the Turkish Version of the Hamilton Depression Rating Scale A. Akdemir, M.H. Türkçapar, S.D. Örsel, N. Demirergi, I. Dag, and M.H. Özbay The aim of the study was to examine
More informationResults. NeuRA Treatments for dual diagnosis August 2016
Introduction Many treatments have been targeted to improving symptom severity for people suffering schizophrenia in combination with substance use problems. Studies of dual diagnosis often investigate
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationIndividual differences in decision-making
Personality and Individual Differences 39 (2005) 991 998 www.elsevier.com/locate/paid Individual differences in decision-making Ingmar H.A. Franken *, Peter Muris Department of Psychology, Erasmus University
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Single Technology Appraisal Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationCharacterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions
Brain (2000), 123, 2189 2202 Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions Antoine Bechara, Daniel Tranel and Hanna Damasio Department of Neurology,
More informationAntidepressant Utilization in Bipolar Disorder: What Is the Evidence?
Antidepressant Utilization in Bipolar Disorder: What Is the Evidence? 2018 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD Lundbeck, LLC March 2018 MRC2.CORP.D.00336 Today s
More informationPrevalence of cognitive impairment in major depression and bipolar disorder
Received: 7 September 2017 Revised: 5 November 2017 Accepted: 15 December 2017 DOI: 10.1111/bdi.12602 ORIGINAL ARTICLE Prevalence of cognitive impairment in major depression and bipolar disorder Katie
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationMethod. NeuRA Schizophrenia and bipolar disorder April 2016
Introduction Schizophrenia is characterised by positive, negative and disorganised symptoms. Positive symptoms refer to experiences additional to what would be considered normal experience, such as hallucinations
More informationA systematic review of the evidence on the treatment of rapid cycling bipolar disorder
Bipolar Disorders 2013: 15: 115 137 Review Article Ó 2013 John Wiley and Sons A/S Published by Blackwell Publishing Ltd. BIPOLAR DISORDERS A systematic review of the evidence on the treatment of rapid
More informationIs decision making really impaired in eating disorders?
Is decision making really impaired in eating disorders? Sébastien Guillaume, Caroline Ngo Ton Sang, Isabelle Jaussent, Isabelle Raingeard, Jacques Bringer, Fabrice Jollant, Philippe Courtet To cite this
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationMapping Neural circuitry of Risk and Resilience for Suicidal Behavior and Mood Disorders
Mapping Neural circuitry of Risk and Resilience for Suicidal Behavior and Mood Disorders J. John Mann, MD Paul Janssen Professor of Translational Neuroscience in Psychiatry and Radiology Columbia University
More informationFinal Exam PSYC2022. Fall (1 point) True or False. The DSM-IV describes the symptoms of acute intoxication with cannabis.
Final Exam PSYC2022 Fall 1998 (2 points) Give 2 reasons why it is important for psychological disorders to be accurately diagnosed. (1 point) True or False. The DSM-IV describes the symptoms of acute intoxication
More informationARTICLE IN PRESS. Ömer AYDEMİR 1, Burak UYKUR 2
Turkish Journal of Psychiatry 2011 Reliability and validity study of the Turkish version of functioning assessment short test in bipolar disorder ARTICLE IN PRESS Ömer AYDEMİR 1, Burak UYKUR 2 SUMMARY
More informationProfessor Tony Holland, Department of Psychiatry, University of Cambridge
INFORMATION SHEET The Use of Medication for Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction Challenging behaviours displayed by people with
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationSocial and Emotional Decision-making Following Frontal Lobe Injury
Neurocase, 10(5): 398 403, 2004 Copyright Taylor & Francis Inc. 1355-4795/04/1005 398$16.00 Neurocase Social and Emotional Decision-making Following Frontal Lobe Injury Luke Clark 1 and Facundo Manes 2
More informationVascular risk factors in late onset mania
Psychological Medicine, 2002, 32, 359 362. 2002 Cambridge University Press DOI: 10.1017 S0033291701004718 Printed in the United Kingdom BRIEF COMMUNICATION Vascular risk factors in late onset mania FREDERICK
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX
A acceptance and commitment therapy Posttraumatic Stress, 69 ADHD Adjunctive Fatty Acids, 5 Adjunctive Guanfacine Pharmacokinetics, 27 Amantadine, 21 Atomoxetine, 23 Cancer Risk, 31 CBT for Comorbid Anxiety,
More informationSuicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative
Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic
More informationAcademic year Lecture 16 Emotions LECTURE 16 EMOTIONS
Course Behavioral Economics Academic year 2013-2014 Lecture 16 Emotions Alessandro Innocenti LECTURE 16 EMOTIONS Aim: To explore the role of emotions in economic decisions. Outline: How emotions affect
More informationCognitive Impairment in Euthymic Bipolar Affective Disorder Patients
Internal Journal of Scientific and Research Publics, Volume 5, Issue 10, October 2015 1 Cognitive Impairment in Euthymic Bipolar Affective Disorder Patients Dr. Mohan Babu M *, Dr. Supriya Hegde Aroor
More informationWhat s new in the treatment of bipolar disorder?
What s new in the treatment of bipolar disorder? Dr. David Cousins MRC Clinician Scientist Institute of Neuroscience Newcastle University NCMD 2017 What s new in the treatment of bipolar disorder? Dr.
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationCIMR. What is the CIMR? May In this issue. Quarterly Newsletter. Volume 1, Issue 2
What is Department of : What is the? The has recently been established at University Health Network to promote the understanding of depression and mood disorders; to develop innovative evidence-based therapeutic
More informationCannabinoids and Mental Health
Cannabinoids and Mental Health https://upload.wikimedia.org/wikipedia/commons Karen M. Lounsbury, PhD Professor of Pharmacology 802-656-3231, Karen.lounsbury@uvm.edu Objectives Describe the underlying
More informationSomatic Marker Hypothesis. Tasha Poppa Affective Computing Guest Lecture Fall 2017
Somatic Marker Hypothesis Tasha Poppa Affective Computing Guest Lecture Fall 2017 Outline Historical context Some Useful Functional Neuroanatomy VMPFC patients: Clinical observations Somatic Marker Hypothesis
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationCognitive and neuroimaging findings in pathological gambling
Cognitive and neuroimaging findings in pathological gambling TNU seminar on Pathological Gambling, 2.11.2012 Jakob Heinzle Translational Neuromodeling Unit (TNU), Institute for Biomedical Engineering (IBT),
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationPractical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current Clinical Guidelines
SECOND-GENERATION ANTIPSYCHOTICS IN BIPOLAR DISORDER Practical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current s Flavio Guzman, MD Editor Psychopharmacology Institute
More informationsmokers) aged 37.3 ± 7.4 yrs (mean ± sd) and a group of twelve, age matched, healthy
Methods Participants We examined a group of twelve male pathological gamblers (ten strictly right handed, all smokers) aged 37.3 ± 7.4 yrs (mean ± sd) and a group of twelve, age matched, healthy males,
More informationRunning head: Cognitive decision models in cocaine abusers. Cognitive modeling analysis of the decision-making processes used by cocaine abusers
Cognitive Decision Models 1 Running head: Cognitive decision models in cocaine abusers Cognitive modeling analysis of the decision-making processes used by cocaine abusers Julie C. Stout, Jerome R. Busemeyer
More informationKing s Research Portal
King s Research Portal DOI: 10.1016/j.encep.2016.04.004 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Yang, H., & Young,
More information4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue
Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University
More informationMedical Treatment of Problem Gambling. Donald W. Black, M.D. Roy J. and Lucille A. Carver College of Medicine Department of Psychiatry
Medical Treatment of Problem Gambling Donald W. Black, M.D. Roy J. and Lucille A. Carver College of Medicine Department of Psychiatry Disclosures Research Support: Forest Labs Nellie Ball Trust Fund National
More informationCognition and functioning in bipolar disorder
Chapter Cognition and functioning in bipolar disorder Chapter Introduction Over the last two decades it has been demonstrated that bipolar patients present both cognitive dysfunctions and difficulties
More informationOut with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications
Program Outline Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine
More informationThe treatment of bipolar disorder in adults, children and adolescents
DRAFT FOR CONSULTATION The treatment of bipolar disorder in adults, children and adolescents The paragraphs in the draft are numbered for the purposes of consultation. The final version will not contain
More informationAPPENDIX 33: HEALTH ECONOMICS ECONOMIC EVIDENCE PROFILES
APPENDIX 33: HEALTH ECONOMICS ECONOMIC EVIDENCE PROFILES 1.1 Case identification assessment of adults with bipolar disorder... 2 1.1.1 Clinical/economic question: Mood Disorder Questionnaire (MDQ) versus
More informationOpen Translational Science in Schizophrenia. Harvard Catalyst Workshop March 24, 2015
Open Translational Science in Schizophrenia Harvard Catalyst Workshop March 24, 2015 1 Fostering Use of the Janssen Clinical Trial Data The goal of this project is to foster collaborations around Janssen
More informationChronic irritability in youth that may be misdiagnosed as bipolar disorder. Ellen Leibenluft, M.D.
Chronic irritability in youth that may be misdiagnosed as bipolar disorder Ellen Leibenluft, M.D. Chief, Section on Bipolar Spectrum Disorders Emotion and Development Branch National Institute of Mental
More informationANXIETY AND DEPRESSIVE NEUROSIS - THEIR RESPONSE TO ANXIOLYTIC AND ANTIDEPRESSANT TREATMENT GURMEET SINGH 1 R. K. SHARMA 2 SUMMARY
Indian Journal of Psychiatry, January 29(1), pp 49-56 ANXIETY AND DEPRESSIVE NEUROSIS - THEIR RESPONSE TO ANXIOLYTIC AND ANTIDEPRESSANT TREATMENT GURMEET SINGH 1 R. K. SHARMA 2 SUMMARY A total of 90 patients
More information590,000 deaths can be attributed to an addictive substance in some way
Mortality and morbidity attributable to use of addictive substances in the United States. The Association of American Physicians from 1999 60 million tobacco smokers in the U.S. 14 million dependent on
More informationMeta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives
SUPPLEMENTARY MATERIAL Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives B. Arts 1 *, N. Jabben 1, L. Krabbendam 1 and J. van Os 1,2 1 Department of Psychiatry
More informationSupplementary Methods
Supplementary Materials for Suicidal Behavior During Lithium and Valproate Medication: A Withinindividual Eight Year Prospective Study of 50,000 Patients With Bipolar Disorder Supplementary Methods We
More informationContemporary Psychiatric-Mental Health Nursing. Psychopharmacology. Psychopharmacology - continued. Chapter 7 The Science of Psychopharmacology
Contemporary Psychiatric-Mental Health Nursing Chapter 7 The Science of Psychopharmacology Psychopharmacology A primary treatment mode of psychiatric-mental health nursing care Psychopharmacology - continued
More informationCognitive Impairment in Bipolar Disorder:
Cognitive Impairment in Bipolar Disorder: What is new in the field? Dr Judy Rubinsztein MBChB, FRCPsych, PhD (Cantab) Bipolar Disorder Benign prognosis? Sub-syndromal symptoms (Judd et al. 2002) Functional
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More informationUniversity of Groningen. Neurological soft signs in schizophrenia and mood disorders Boks, Marco Paul Maria
University of Groningen Neurological soft signs in schizophrenia and mood disorders Boks, Marco Paul Maria IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationAre they still doing that?
Are they still doing that? Why we still give ECT and when to refer Nicol Ferrier BSc (Hons), MD, FRCP(Ed), FRCPsych Emeritus Professor of Psychiatry Newcastle University Rates of prescribing ECT in the
More informationFunctional Impairment and Disability across Mood States in Bipolar Disordervhe_
Volume 13 Number 8 2010 VALUE IN HEALTH Functional Impairment and Disability across Mood States in Bipolar Disordervhe_768 984..988 Adriane R. Rosa, PharmD, PhD, 1 María Reinares, PsycD, PhD, 1 Erin E.
More informationEarly intervention in Bipolar Disorder
Early intervention in Bipolar Disorder Lakshmi N. Yatham MBBS, FRCPC, MRCPsych Professor of Psychiatry, University of British Columbia, Vancouver, Canada Early Intervention in Bipolar Disorder High Risk
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Age as factor in selective mutism, 623 as factor in social phobia, 623 Agoraphobia, 593 600 described, 594 596 DSM-V changes related to,
More informationComparison between Carbamazepine and Divalproate on the Improvement of Clinical Symptoms of Bipolar Mania with Psychotic Feature
International Journal of Clinical sychiatry 2018, 6(2): 34-39 DOI: 10.5923/j.ijcp.20180602.02 Comparison between and on the Improvement of Clinical Symptoms of Bipolar Mania with sychotic Feature Sonny
More informationDecision-making and addiction (part II): myopia for the future or hypersensitivity to reward?
Neuropsychologia 40 (2002) 1690 1705 Decision-making and addiction (part II): myopia for the future or hypersensitivity to reward? Antoine Bechara a,, Sara Dolan b, Andrea Hindes a a Department of Neurology,
More informationHHS Public Access Author manuscript Bipolar Disord. Author manuscript; available in PMC 2016 June 01.
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression Dawn F Ionescu a,b, David A Luckenbaugh c, Mark J Niciu c, Erica M Richards c, and Carlos A Zarate Jr
More informationAnorexia, bulimia, and obesity: Shared decision making deficits on the Iowa Gambling Task (IGT)
Journal of the International Neuropsychological Society (2010), 16, 711 715. Copyright INS. Published by Cambridge University Press, 2010. doi:10.1017/s1355617710000354 BRIEF COMMUNICATION Anorexia, bulimia,
More informationMale Sexual Dysfunction in Psychiatric Illnesses Sujit Kumar Kar 1, Saranya Dhanasekaran 1 Correspondence: gmail.
RESEARCH ARTICLE Open Access Male Sexual Dysfunction in Psychiatric Illnesses Sujit Kumar Kar 1, Saranya Dhanasekaran 1 Correspondence: drsujita@gmail.com; saranya296@ gmail.com Full list of author information
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationBrain Imaging studies in substance abuse. Jody Tanabe, MD University of Colorado Denver
Brain Imaging studies in substance abuse Jody Tanabe, MD University of Colorado Denver NRSC January 28, 2010 Costs: Health, Crime, Productivity Costs in billions of dollars (2002) $400 $350 $400B legal
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 November 2011 SYCREST 5 mg, sublingual tablet B/60 (CIP code: 415 241-6) B/100 (CIP code: 579 353-1) SYCREST 10
More informationSchizophrenia FAHAD ALOSAIMI
Schizophrenia FAHAD ALOSAIMI MBBS, SSC - PSYCH C ONSULTATION LIAISON PSYCHIATRIST K ING SAUD UNIVERSITY Schizophrenia - It is not a single disease but a group of disorders with heterogeneous etiologies.
More informationUnderstanding and Treating Behavioral Addictions
Understanding and Treating Behavioral Addictions Jon Grant, MD, JD, MPH Professor of Psychiatry and Behavioral Neuroscience University of Chicago Chicago, Illinois Disclosure The faculty have been informed
More informationUsing stochastic differential equations to model the ups and downs of patients with bipolar disorder for clinical purposes
Introduction Using stochastic differential equations to model the ups and downs of patients with bipolar disorder for clinical purposes Nicole Kennerly, BBSI @ Pitt Mentor: Shlomo Ta asan, Carnegie Mellon
More informationasenapine 5mg, 10mg sublingual tablet (Sycrest ) SMC No. (762/12) Lundbeck Ltd
asenapine 5mg, 10mg sublingual tablet (Sycrest ) SMC No. (762/12) Lundbeck Ltd 10 February 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More informationCONFLICT OF INTEREST OBJECTIVES BIPOLAR DISORDER, OVERVIEW BIPOLAR DISORDER 3/26/2018 TREATMENT OF RAPID-CYCLING BIPOLAR DISORDER
TREATMENT OF RAPID-CYCLING BIPOLAR DISORDER PAMELA MARCUS, RN,APRN/PMH/BC 14460 Old Mill Rd. #201 Upper Marlboro, Maryland 20772 marcusrn@verizon.net CONFLICT OF INTEREST Ms. Marcus has no conflicts of
More information